These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 8641613

  • 1. Octreotide in the management of bowel obstruction in terminal ovarian cancer.
    Mangili G, Franchi M, Mariani A, Zanaboni F, Rabaiotti E, Frigerio L, Bolis PF, Ferrari A.
    Gynecol Oncol; 1996 Jun; 61(3):345-8. PubMed ID: 8641613
    [Abstract] [Full Text] [Related]

  • 2. [A clinical study using octreotide in relieving gastrointestinal symptoms due to bowel obstruction in a terminally ill cancer patient].
    Shima Y, Yamaguchi K, Miyata Y, Hyodo I, Yagi Y, Honke Y.
    Gan To Kagaku Ryoho; 2004 Sep; 31(9):1377-82. PubMed ID: 15446560
    [Abstract] [Full Text] [Related]

  • 3. Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction.
    Hisanaga T, Shinjo T, Morita T, Nakajima N, Ikenaga M, Tanimizu M, Kizawa Y, Maeno T, Shima Y, Hyodo I.
    Jpn J Clin Oncol; 2010 Aug; 40(8):739-45. PubMed ID: 20410056
    [Abstract] [Full Text] [Related]

  • 4. Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer.
    Matulonis UA, Seiden MV, Roche M, Krasner C, Fuller AF, Atkinson T, Kornblith A, Penson R.
    J Pain Symptom Manage; 2005 Dec; 30(6):563-9. PubMed ID: 16376743
    [Abstract] [Full Text] [Related]

  • 5. Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double- blind, controlled clinical trial.
    Mystakidou K, Tsilika E, Kalaidopoulou O, Chondros K, Georgaki S, Papadimitriou L.
    Anticancer Res; 2002 Dec; 22(2B):1187-92. PubMed ID: 12168923
    [Abstract] [Full Text] [Related]

  • 6. Pathophysiology and palliation of inoperable bowel obstruction in patients with ovarian cancer.
    Jatoi A, Podratz KC, Gill P, Hartmann LC.
    J Support Oncol; 2004 Dec; 2(4):323-34; discussion 334-7. PubMed ID: 15357517
    [Abstract] [Full Text] [Related]

  • 7. Clinical efficacy and safety of octreotide (SMS201-995) in terminally ill Japanese cancer patients with malignant bowel obstruction.
    Shima Y, Ohtsu A, Shirao K, Sasaki Y.
    Jpn J Clin Oncol; 2008 May; 38(5):354-9. PubMed ID: 18490369
    [Abstract] [Full Text] [Related]

  • 8. A prospective study on the efficacy of octreotide in the management of malignant bowel obstruction in gynecologic cancer.
    Watari H, Hosaka M, Wakui Y, Nomura E, Hareyama H, Tanuma F, Hattori R, Azuma M, Kato H, Takeda N, Ariga S, Sakuragi N.
    Int J Gynecol Cancer; 2012 May; 22(4):692-6. PubMed ID: 22343971
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer.
    Peng X, Wang P, Li S, Zhang G, Hu S.
    World J Surg Oncol; 2015 Feb 15; 13():50. PubMed ID: 25889313
    [Abstract] [Full Text] [Related]

  • 11. SALTO: a randomized, multicenter study assessing octreotide LAR in inoperable bowel obstruction.
    Laval G, Rousselot H, Toussaint-Martel S, Mayer F, Terrebonne E, François E, Brixi H, Nguyen T, Bourdeix I, Bisot-Locard S, Zelek L, SALTO Study Group.
    Bull Cancer; 2012 Feb 01; 99(2):E1-9. PubMed ID: 22265994
    [Abstract] [Full Text] [Related]

  • 12. Octreotide for malignant bowel obstruction: twenty years after.
    Mercadante S, Porzio G.
    Crit Rev Oncol Hematol; 2012 Sep 01; 83(3):388-92. PubMed ID: 22277783
    [Abstract] [Full Text] [Related]

  • 13. Malignant irreversible intestinal obstruction: the powerful association of octreotide to corticosteroids, antiemetics, and analgesics.
    Weber C, Zulian GB.
    Am J Hosp Palliat Care; 2009 Sep 01; 26(2):84-8. PubMed ID: 19088264
    [Abstract] [Full Text] [Related]

  • 14. Sustained release octreotide may have a role in the treatment of malignant bowel obstruction.
    Massacesi C, Galeazzi G.
    Palliat Med; 2006 Oct 01; 20(7):715-6. PubMed ID: 17060271
    [Abstract] [Full Text] [Related]

  • 15. [Clinical efficacy of octreotide acetate in cancer patients with malignant bowel symptoms depend on terminal stage].
    Uchino R, Kusano S, Hanada N, Ohara C, Okino T, Yamaguchi K.
    Gan To Kagaku Ryoho; 2011 Feb 01; 38(2):255-7. PubMed ID: 21368489
    [Abstract] [Full Text] [Related]

  • 16. [A case of successful treatment using octreotide acetate for occlusive ileus in terminal stage cancer].
    Yoshioka S, Tsujie M, Ebisui C, Okubo K, Akitake H, Otsuka M, Maekawa T, Hama N, Kashiwazaki M, Taniguchi M, Konishi M, Fujimoto T.
    Gan To Kagaku Ryoho; 2009 Nov 01; 36(12):2266-8. PubMed ID: 20037391
    [Abstract] [Full Text] [Related]

  • 17. Octreotide improved the quality of life in a child with malignant bowel obstruction caused by peritoneal dissemination of colon cancer.
    Watanabe H, Inoue Y, Uchida K, Okugawa Y, Hiro J, Ojima E, Kobayashi M, Miki C, Kusunoki M.
    J Pediatr Surg; 2007 Jan 01; 42(1):259-60. PubMed ID: 17208578
    [Abstract] [Full Text] [Related]

  • 18. Management of malignant bowel obstruction.
    Ripamonti CI, Easson AM, Gerdes H.
    Eur J Cancer; 2008 May 01; 44(8):1105-15. PubMed ID: 18359221
    [Abstract] [Full Text] [Related]

  • 19. How to use octreotide for malignant bowel obstruction.
    Ripamonti C, Mercadante S.
    J Support Oncol; 2004 May 01; 2(4):357-64. PubMed ID: 15357519
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.